Comparative Pharmacology
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus OXYBUTYNIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus OXYBUTYNIN.
ANISOTROPINE METHYLBROMIDE vs OXYBUTYNIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anisotropine methylbromide is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors (M1, M2, M3), thereby inhibiting parasympathetic nerve impulses. This leads to relaxation of smooth muscle in the gastrointestinal tract, decreased gastric acid secretion, and reduced motility.
Oxybutynin is an anticholinergic agent that competitively antagonizes muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the bladder detrusor muscle, inhibiting involuntary contractions and increasing bladder capacity.
Adult: 1-2 mg intramuscularly or subcutaneously every 4-6 hours as needed. Maximum: 8 mg/day.
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (3 pumps) applied once daily.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateOxybutynin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Fluconazole
Terminal elimination half-life is approximately 1.5-2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours).
Terminal half-life: 12-13 hours (range 7-20 hours) in healthy adults. In elderly, half-life may be prolonged due to reduced clearance.
Primarily renal (approx. 70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%, mainly as metabolites.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are mainly excreted renally (50%) and fecally (40%).
Category C
Category A/B
Anticholinergic
Anticholinergic
"The metabolism of Fluconazole can be decreased when combined with Oxybutynin."